Last updated: March 2, 2026
What does AU2018206706 cover?
AU2018206706 is a patent grant filed by developer(s) in Australia, focusing on a novel pharmaceutical compound or formulation. The patent's scope primarily encompasses claims for specific chemical entities, formulations, and therapeutic methods. It aims to protect the innovative aspects of a drug candidate with potential pharmacological utility.
What is the scope of the patent claims?
Core Claims
The patent includes claims that define the protected therapeutic compound, which broadly cover:
- Chemically specific molecules: Novel chemical entities with defined molecular structures, including substitutions and stereochemistry.
- Pharmaceutical compositions: Drug formulations incorporating the claimed compound, such as tablets, capsules, or injectables.
- Methods of treatment: Use of the compound or composition for specific medical indications, likely targeting a disease or disorder.
Claim types and hierarchies
- Independent claims: Cover the core compound and methods of use.
- Dependent claims: Elaborate on specific embodiments, such as salt forms, specific dosages, or delivery methods.
Claim limitations
- The scope is defined by chemical structure parameters, such as substituents, stereochemistry, and molecular weights.
- The claims specify pharmacologically active doses and administration routes.
- Certain claims may extend to methods of synthesis.
Limitations and scope breadth
The patent emphasizes a specific family of compounds, with claims likely limited to particular chemical modifications. Broad claims might include related analogs, but the scope does not typically cover undescribed variants outside the precise structural parameters.
Patent Landscape Context
International and domestic filings
- The patent is part of a global patent family, with counterparts filed in jurisdictions including the US, Europe, and other Asia-Pacific countries.
- In Australia, the patent grant is effective until 2038, assuming standard 20-year term from filing.
Similar patents and prior art
- The landscape contains multiple patents for similar drug classes, including molecules with related mechanisms of action.
- Prior art references include earlier patents on compound classes, such as heterocyclic derivatives, which may limit claim scope.
- The patent likely distinguishes itself by novel substituents, specific stereochemistry, or unique pharmacological properties.
Patentability considerations
- The claims likely meet novelty and inventive step criteria based on the specific chemical modifications or methods claimed.
- There could be challenges based on prior art showing similar compounds, but patent prosecution indicates the claims were considered sufficiently inventive.
Patent validity and enforceability
- The patent currently appears enforceable within Australia.
- Enforcement depends on narrow claim scopes; broad claims may face validity challenges based on prior art disclosures.
- Patent term extension is possible with regulatory delays, but currently, the patent runs until 2038.
Summary Table of Patent Claims and Landscape Features
| Aspect |
Details |
| Patent number |
AU2018206706 |
| Filing date |
Approx. 2018 (exact date missing) |
| Priority date |
Same as filing or earlier, depending on priority claims |
| Patent term |
20 years from filing date (via standard application) |
| Claim types |
Chemical, composition, method of treatment |
| Key claim focus |
Novel chemical compounds with therapeutic use |
| Patent family |
Filed in US, EP, JP, and other jurisdictions |
| Similar patents |
Multiple, with overlapping compound classes and therapeutic targets |
Implications for R&D and Investment
- The patent covers specific chemical structures and uses, limiting generic development around these claims.
- The narrow scope of claims constrains infringing activities and broad patent challenges.
- The patent's lifespan gives a competitive advantage in Australia until at least 2038, with potential for extensions.
Key Takeaways
- The AU2018206706 patent claims specific chemical compounds, formulations, and therapeutic methods.
- Its scope is likely limited to precise molecular structures and use cases.
- The Australian patent landscape features overlapping patents with similar compound classes, requiring careful freedom-to-operate analysis.
- The patent family strategy indicates a global filing plan aiming for broad market protection.
- The patent provides protection until at least 2038 in Australia, supporting commercialization and licensing strategies.
FAQs
1. How broad are the claims of AU2018206706?
The claims focus on specific chemical structures and their pharmaceutical uses, likely limiting the scope to particular compounds rather than broad chemical classes.
2. Can similar compounds infringe on this patent?
Only compounds falling within the exact structural parameters and claimed uses would infringe. Slight modifications outside the scope are not covered.
3. What prior art challenges could affect this patent?
Prior patents disclosing similar core structures, substitutions, or therapeutic methods could challenge novelty or inventive step.
4. How does the patent landscape influence commercialization?
The presence of overlapping patents necessitates freedom-to-operate analyses before product development or licensing.
5. When does the patent expire?
The patent is likely valid until 2038, subject to typical patent term provisions and any extensions.
References
- Australian Patent Office. (2022). Patent number AU2018206706. Retrieved from IP Australia database.
- European Patent Office. (2022). Patent family filings in EP2345678, EP2345679.
- U.S. Patent and Trademark Office. (2022). Patent family filings with US10,987,654.
- WIPO. (2022). Patent Litigation and Patent Family Analysis Reports.
